Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Genetically engineered models have advantages over xenografts for preclinical studies.

Becher OJ, Holland EC.

Cancer Res. 2006 Apr 1;66(7):3355-8, discussion 3358-9. Erratum in: Cancer Res. 2006 May 15;66(10):5526.

2.

Harnessing genetically engineered mouse models for preclinical testing.

Robles AI, Varticovski L.

Chem Biol Interact. 2008 Jan 30;171(2):159-64. Epub 2007 Feb 8. Review.

PMID:
17362899
4.

Genetically modified mouse models for biomarker discovery and preclinical drug testing.

Kucherlapati R.

Clin Cancer Res. 2012 Feb 1;18(3):625-30. doi: 10.1158/1078-0432.CCR-11-2021.

5.

Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.

Hansen K, Khanna C.

Eur J Cancer. 2004 Apr;40(6):858-80. Review.

PMID:
15120042
6.
7.
8.

Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer.

Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC.

Cancer Biol Ther. 2007 Nov;6(11):1717-25. Epub 2007 Aug 3.

PMID:
17986851
9.

The mighty mouse: genetically engineered mouse models in cancer drug development.

Sharpless NE, Depinho RA.

Nat Rev Drug Discov. 2006 Sep;5(9):741-54. Epub 2006 Aug 18. Review.

PMID:
16915232
10.

Faithful companions: a proposal for neurooncology trials in pet dogs.

Kimmelman J, Nalbantoglu J.

Cancer Res. 2007 May 15;67(10):4541-4.

11.

50 years of preclinical anticancer drug screening: empirical to target-driven approaches.

Suggitt M, Bibby MC.

Clin Cancer Res. 2005 Feb 1;11(3):971-81. Review.

12.

In vivo models of childhood leukemia for preclinical drug testing.

Bachmann PS, Lock RB.

Curr Drug Targets. 2007 Jun;8(6):773-83. Review.

PMID:
17584033
13.

Contributions of human tumor xenografts to anticancer drug development.

Sausville EA, Burger AM.

Cancer Res. 2006 Apr 1;66(7):3351-4, discussion 3354. Review.

14.

[Preclinical evaluation of anticancer drugs: a model remaining a model!].

Lavelle F.

Bull Cancer. 1998 Oct;85(10):837-42. French.

15.

Cancer modeling in the modern era: progress and challenges.

Van Dyke T, Jacks T.

Cell. 2002 Jan 25;108(2):135-44. Review.

16.

Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.

Muruganandham M, Lupu M, Dyke JP, Matei C, Linn M, Packman K, Kolinsky K, Higgins B, Koutcher JA.

Mol Cancer Ther. 2006 Aug;5(8):1950-7.

17.

Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.

Peterson JK, Houghton PJ.

Eur J Cancer. 2004 Apr;40(6):837-44. Review.

PMID:
15120039
18.

The use of xenograft models for the selection of cancer treatments with the EGFR as an example.

Troiani T, Schettino C, Martinelli E, Morgillo F, Tortora G, Ciardiello F.

Crit Rev Oncol Hematol. 2008 Mar;65(3):200-11. Review.

PMID:
18389522
19.

Technologically advanced cancer modeling in mice.

Tuveson DA, Jacks T.

Curr Opin Genet Dev. 2002 Feb;12(1):105-10. Review.

PMID:
11790563
20.

Practical development of genetically engineered animals as human disease models.

Nomura T.

Lab Anim Sci. 1997 Apr;47(2):113-7. Review.

PMID:
9150486

Supplemental Content

Support Center